Equities

Oncimmune Holdings PLC

ONC:LSE

Oncimmune Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)11.15
  • Today's Change0.00 / 0.00%
  • Shares traded35.50k
  • 1 Year change-27.83%
  • Beta0.7001
Data delayed at least 20 minutes, as of Jun 27 2024 14:54 BST.
More ▼

Profile data is unavailable for this security.

About the company

Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.

  • Revenue in GBP (TTM)1.21m
  • Net income in GBP-3.19m
  • Incorporated2015
  • Employees56.00
  • Location
    Oncimmune Holdings PLC1 Park RowLEEDS LS1 5ABUnited KingdomGBR
  • Phone+44 11 5823 1869Fax+44 11 5823 1958
  • Websitehttps://www.oncimmune.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
BSF Enterprise PLC67.24k-1.71m5.68m4.005.68m4.00
Cizzle Biotechnology Holdings PLC0.00-1.72m6.74m67.006.74m67.00
Oncimmune Holdings PLC1.21m-3.19m8.34m56.008.34m56.00
Cambridge Nutritional Sciences PLC9.05m-3.21m8.69m91.008.69m91.00
ImmuPharma PLC0.00-2.92m8.93m5.008.93m5.00
Genflow Biosciences PLC0.00-1.63m9.09m5.009.09m5.00
Kanabo Group PLC895.00k-7.99m9.17m20.009.17m20.00
Destiny Pharma PLC0.00-5.66m9.38m19.009.38m19.00
Bivictrix Therapeutics PLC0.00-2.55m10.32m10.0010.32m10.00
Chill Brands Group PLC146.62k-3.64m10.89m2.0010.89m2.00
Synairgen plc0.00-9.99m11.23m30.0011.23m30.00
Genincode PLC2.16m-7.02m11.95m36.0011.95m36.00
Proteome Sciences plc5.03m-2.44m12.25m35.0012.25m35.00
Data as of Jun 27 2024. Currency figures normalised to Oncimmune Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

9.86%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 31 Aug 20233.14m4.23%
Chelverton Asset Management Ltd.as of 31 Aug 20233.01m4.06%
Unicorn Asset Management Ltd.as of 31 May 20241.16m1.57%
Gabelli Funds LLCas of 28 Mar 20242.90k0.00%
More ▼
Data from 30 Sep 2023 - 03 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.